Stryker (NYSE:SYK) Stock Gets Price Target Cut from BTIG Research

Stryker (NYSE:SYK) had its price objective decreased by BTIG Research from $358.00 to $316.00 in a report issued on Monday, MarketBeat.com reports. BTIG Research currently has a buy rating on the medical technology company’s stock.

Several other brokerages have also recently issued reports on SYK. Sanford C. Bernstein reiterated a “market perform” rating on shares of Stryker in a research note on Wednesday, October 7th. Evercore set a $350.00 price target on Stryker in a research report on Monday, July 6th. TD Cowen lowered their price objective on Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a research note on Tuesday, September 22nd. Royal Bank Of Canada lowered their price objective on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Finally, Stifel Nicolaus dropped their price objective on Stryker from $360.00 to $330.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $369.00.

Stryker Price Performance

Shares of Stryker stock opened at $281.78 on Monday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $108.08 billion, a price-to-earnings ratio of 29.20, a price-to-earnings-growth ratio of 1.79 and a beta of 0.78. Stryker has a twelve month low of $267.00 and a twelve month high of $392.55. The company has a 50-day simple moving average of $301.07 and a two-hundred day simple moving average of $313.22.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the prior year, the business posted $3.13 EPS. The business’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts forecast that Stryker will post 14.95 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Activity

In related news, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Institutional Trading of Stryker

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sankala Group LLC bought a new position in shares of Stryker during the 4th quarter valued at about $26,000. Gables Capital Management Inc. purchased a new position in shares of Stryker during the 2nd quarter valued at about $25,000. Kilter Group LLC bought a new stake in Stryker in the 2nd quarter worth approximately $25,000. Cornerstone Financial Management LLC lifted its position in Stryker by 66.0% in the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after buying an additional 31 shares during the last quarter. Finally, Highland Investment Advisors LLC purchased a new stake in Stryker in the second quarter worth approximately $25,000. Institutional investors own 77.09% of the company’s stock.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker received FDA 510(k) clearance for Sonopet 3, an ultrasonic tissue-removal system designed to provide greater power, precision and versatility in bone and soft-tissue procedures. The launch could support future revenue growth and strengthen Stryker’s surgical portfolio. Stryker launches Sonopet 3
• Positive Sentiment: Stryker is investing $400 million in CMR Surgical and obtaining exclusive U.S. sales rights for the Versius robotic-assisted surgery system, with an option to acquire the company. The deal expands Stryker into soft-tissue robotics and could create a new growth platform, although it also involves execution and investment risks. Stryker and CMR Surgical robotics deal
• Positive Sentiment: Leerink Partners maintained its Buy rating on SYK, suggesting the analyst remains constructive on the company’s operating outlook and long-term growth prospects. Leerink Partners maintains Buy rating
• Neutral Sentiment: Stryker is scheduled to report third-quarter results on October 29. Investors will focus on procedure volumes, organic sales growth, margins and whether the company remains on track for its fiscal 2026 EPS guidance of $14.95–$15.10. Stryker earnings preview
• Negative Sentiment: Law firms including Frank R. Cruz and Pomerantz announced investigations into potential violations of federal securities laws. The announcements do not establish wrongdoing, but they may increase legal uncertainty, reputational risk and volatility for SYK while investors await more details. Securities fraud investigation into Stryker

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.

Stryker’s product portfolio includes orthopedic implants and instruments, surgical equipment, neurovascular devices, spine products, patient-handling and emergency-care equipment, operating-room systems, and digital and robotic technologies.